Teneligliptin As an Initial Therapy for Newly Diagnosed, Drug Naive Subjects With Type 2 Diabetes

BACKGROUND: Teneligliptin is a novel, highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor. The aim of this study is to explore the glycemic and non-glycemic efficacies of teneligliptin as an initial therapy. METHODS: Newly diagnosed, drug naive Japanese subjects with type 2 diabetes (T2DM) wer...

Descripción completa

Detalles Bibliográficos
Autores principales: Kutoh, Eiji, Hirate, Mitsuru, Ikeno, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2014
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039101/
https://www.ncbi.nlm.nih.gov/pubmed/24883155
http://dx.doi.org/10.14740/jocmr1841e

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039101/
https://www.ncbi.nlm.nih.gov/pubmed/24883155
http://dx.doi.org/10.14740/jocmr1841e

Ejemplares similares